A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort 1), and in patients with advanced and/or metastatic SCCHN (Cohort 2). The overall study will be comprised of two phases, a Dose Escalation Phase, and a Cohort Expansion Phase.

Sponsor

Wugen, Inc.

Status of enrollment

Accepting new patients

Ages Eligible for Study

Adults aged 18 and older

Genders Eligible for Study

Female and Male

Disease indication

Colorectal Cancer Metastatic

Squamous Cell Carcinoma of Head and Neck

Principal Investigator

Bridget Keenan, MD, PhD

Contact

Sylvan Muellerleile

[email protected]

 

Additional study eligibility details can be found at UCSF Clinical Trials.